


**'Beneficiary Advisory Panel Handout  
Uniform Formulary Decisions  
24 Sept 2009**

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

**Table 1: Uniform Formulary Recommendations from the Aug 2009  
DoD P&T Committee Meeting**

UF Status / Implementation Period	Brand Name (Generic)
<b>Phosphodiesterase Type 5 Inhibitors (PDE-5 inhibitors) for Erectile Dysfunction</b>	
<b>Formulary</b>	BCF: Levitra (vardenafil)
<b>Non-Formulary</b>	Viagra (sildenafil)
	Cialis (tadalafil)
<b>Recommended implementation period</b>	60 days

**Figure 1**




SOURCE: PDTS

**Table 2: Simponi (golimumab) and Cimzia (certolizumab) Uniform Formulary Recommendations from Aug 2009 for the Targeted Immunomodulatory Biologics (TIBs)**

Targeted Immunomodulatory Biologics (TIBs)			
UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Formulary	ECF: Humira (adalimumab)	SQ	No
	UF: Raptiva(efalizumab)	SQ	No
	UF: Amevive (alefacept)	IM/IV	No
Non Formulary	Enbrel (etanercept)	SQ	No
	Kineret (anakinra)	SQ	No
	Cimzia (certolizumab )	SQ	No
	Simponi (golimumab)	SQ	No
Recommended implementation period	60 days for Cimzia and Simponi		

SQ = subcutaneous IM= intramuscular IV intravenous

**Figure 2**




SOURCE: PDTS

**Table 3: Armodafinil (Nuvigil): Uniform Formulary Recommendations from Aug 2009 for the Narcolepsy Drug Class**

Narcolepsy Drug Class			
UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Formulary	Nuvigil (Armodafinil)	Tabs	No
	Provigil (Modafinil)	Tabs	No
	Xyrem (Sodium Oxybate)	Soln	No
Non Formulary	None		
Recommended implementation period	None		

**Figure 3:**




SOURCE: PDTS

**Table 4: Silodosin (Rapiflo): Uniform Formulary Recommendations from Aug 2009 for the Alpha-1 blocker BPH Agents**

Alpha-1 blocker BPH Agents			
UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Formulary	BCF: Uroxatral (alfuzosin)	extended release cap	No
	BCF: Hytrin (terazosin)	tab/cap	Yes
	Cardura (doxazosin)	tab	Yes
Non-formulary	Flomax (tamsulosin)	cap	No
	Rapiflo (silodosin)	cap	No
Recommended implementation period	60 days for Rapiflo		

**Figure 4:**

## Utilization - All POS Jun 07 – Jul 09



SOURCE: PDTs

**Table 5: Recommended to retain formulary on Uniform Formulary**

ProdName	Subclass	Manufacturer	Sum of Patients
ACTIMMUNE	Immunomodulators	INTERMUNE	25
APOKYN	Parkinsons medications	TERCICA INC	47
DERMA-SMOOTH-ES	Topical corticosteroids	HILL DERM	1421
DERMOTIC	Otic medications anti-inflammatory	HILL DERM	1886
INTAL	Mast cell stabilizers, inhalation	KING PHARM	439
PANRETIN	Topical antineoplastic & premalignant lesion medic	EISAI INC.	1
RADIOGARDASE	Radiation exposure (cesium, thallium)	HEYLTEX CORPORA	
STROMECTOL	Anthelmintic	MERCK & CO.	514
THIOLA	Kidney stone agents	MISSION PHARM.	12
VANCOICIN HCL	Misc antibiotics	VIROPHARMA INCO	1491
<b>Grand Total</b>			<b>5836</b>

**Table 6: Recommended to retain or be designated non-formulary on Uniform Formulary**

ProdName	Subclass	Manufacturer	Sum of Patients
ACIPHEX	PPIs	EISAI INC.	25,129
ACLOVATE	Topical corticosteroids	Pharmaderm	1
AGRYLIN	Platelet reducing agents	SHIRE US INC.	8
ALA-HIST	1st gen AH	POLY PHARM.	216
ALA-HIST D	1st gen AH-decongestant	POLY PHARM.	590
ALTACE	ACE inhibitors	MONARCH PHRM	69
ANAPROX	NSAIDs	ROCHE LABS.	
ANAPROX DS	NSAIDs	ROCHE LABS.	3
ANDROID	Androgens/anabolic steroids	VALEANT	57
APTIVUS	HIV antivirals, protease inhibitors	BOEHRINGER ING.	6
ATROVENT	Nasal anticholinergics	BOEHRINGER ING.	11
ATROVENT HFA	Inhaled anticholinergics	BOEHRINGER ING.	3,565
AZOR	ARB / CCB combo	DAIICHI SANKYO,	4,471
BREVOXYL-4	Keratolytics	STIEFEL LABS.	296
BREVOXYL-8	Keratolytics	STIEFEL LABS.	325
BROVEX	1st gen antihistamines	MCR/AMERICAN PH	1
BROVEX CT	1st gen antihistamines	MCR/AMERICAN PH	
BROVEX SR	1st gen AH-decongestant	MCR/AMERICAN PH	
BROVEX-D	1st gen AH-decongestant	MCR/AMERICAN PH	
BUPHENYL	Ammonia inhibitors	MEDICIS DERM	7
CADUET	Statin/CCB combo	PFIZER US PHARM	129
CARBATROL	Anticonvulsants	SHIRE US INC.	1,311
CARNITOR	Metabolic deficiency agents	SIGMA-TAU	15
CARNITOR SF	Metabolic deficiency agents	SIGMA-TAU	2
CATAPRES	Sympatholytics	BOEHRINGER ING.	19
CETROTIDE	LHRH (GNRH) antagonist, pituitary suppressant agen	EMD SERONO, INC	34
CHROMAGEN	Iron replacement	THER-RX	511
CHROMAGEN FORTE	Iron replacement	THER-RX	225
CORDRAN	Topical corticosteroids	AQUA PHARMACEUT	145
CORGARD	Beta blockers	KING PHARM	42
CORTISPORIN	Otic medications, anti-infective	MONARCH PHRM	3
	Topical antibiotics & combos	MONARCH PHRM	298
CUTIVATE	Topical corticosteroids	Pharmaderm	1,355
CYTOMEL	Thyroid replacement	KING PHARM	2,955
CYTOXAN	Alkylating agents	BMS ONCO/IMMUN	
DAYTRANA	ADHD medications	SHIRE US INC.	2,700
DECLOMYCIN	Tetracyclines	STONEBRIDGE PHA	2
DEGARELIX	Antineoplastic LHRH agonists	FERRING PH INC	
DEPAKENE	Anticonvulsants	ABBOTT LABS.	12
DERMA-SMOOTH-ES	Topical corticosteroids	HILL DERM	2,239

**Table 6: (cont) Recommended to retain or be designated non-formulary on Uniform Formulary**

ProdName	Subclass	Manufacturer	Sum of Patients
DIBENZYLINE	Alpha blockers, cardiovascular	WELLSPRING PHAR	46
DIPENTUM	Medications for inflammatory bowel disease	ALAVEN PHARMACE	3
DYNEX 12	antitussive-decongestant	ATHLON PHARM	
DYNEX LA	decongestant-expectorant	ATHLON PHARM	4
DYNEX VR	antitussive-expectorant	ATHLON PHARM	
DYRENIUM	Potassium sparing diuretics	WELLSPRING PHAR	277
ELDEPRYL	Parkinsons medications	SOMERSET PHARM	1
ELESTRIN	Estrogens	AZUR PHARMA, IN	26
ELIGARD	Antineoplastic LHRH agonists	SANOFI PHARM	20
EMSAM	MAOIs	BMS PRIMARYCARE	137
ENDOMETRIN	Pregnancy facilitating/maintaining agent	FERRING PH INC	350
ESTRACE	Vaginal estrogen preparations	WC PROF PRODS	8,663
EURAX	Topical antiparasitics	RANBAXY BRAND D	54
EVOXAC	Parasympathetic agents	DAIICHI SANKYO,	1,399
EXELDERM	Topical antifungals	RANBAXY BRAND D	231
FIORICET	Analgesic combos	WATSON PHARMA	300
FLEXERIL	Skeletal muscle relaxants	MC NEIL CONS.	1
FLOMAX	selective alpha blockers for BPH	BOEHRINGER ING.	29,039
FLOXIN	Otic medications, anti-infective	DAIICHI SANKYO,	77
FOSRENOL	Phosphate binders	SHIRE US INC.	635
GESTICARE	Prenatal vitamins	AZUR PHARMA, IN	57
GYNAZOLE-1	Vaginal antifungals	THER-RX	908
HALOG	Topical corticosteroids	RANBAXY BRAND D	261
HEMATRON	Iron replacement	SEYER INC.	22
HEMATRON-AF	Iron replacement	SEYER INC.	131
HYCODAN	antitussive-anticholinergic	ENDO PHARM INC.	
INTELENCE	HIV antivirals, NNRTIs	ORTHO BIOTECH	20
KADIAN	Higher potency single analgesic agents	ALPHARMA BPD	1,512
KAON-CL 10	Potassium replacement	SAVAGE LAB.	35
KAPIDEX	PPIs	TAKEDA PHARM	1,435
KENALOG	Topical corticosteroids	RANBAXY BRAND D	638
KINERET	Targeted immunomodulatory biologics	BIOVITRUM	27
KLONOPIN	Anticonvulsants	ROCHE LABS.	199
K-PHOS NO.2	Urinary pH modifiers	BEACH PRODUCTS	7
K-PHOS ORIGINAL	Urinary pH modifiers	BEACH PRODUCTS	85
KYTRIL	5HT3 antiemetics	ROCHE LABS.	3
LAC-HYDRIN	Emollients	RANBAXY BRAND D	25
LACTINOL	Emollients	PEDINOL PHARM.	13
LACTINOL-E	Emollients	PEDINOL PHARM.	22
LEVULAN	Acne meds	DUSA PHARM	
LIALDA	Medications for inflammatory bowel disease	SHIRE US INC.	1,677
LIMBITROL	TCAs & combos	VALEANT	
LITHOSTAT	Ammonia inhibitors	MISSION PHARM.	1
LOCOID	Topical corticosteroids	TRIAx PHARMACEU	
LUVERIS	Luteinizing hormones	EMD SERONO, INC	17
METANX	Vitamin B preparations	PAN AMERICAN	7,475
MICRO-K	Potassium replacement	THER-RX	55
MINOCIN	Tetracyclines	TRIAx PHARMACEU	
MIRAPEX	Parkinsons medications	BOEHRINGER ING.	8,405
MOBIC	NSAIDs	BOEHRINGER ING.	18
MONODOX	Tetracyclines	AQUA PHARMACEUT	2
MS CONTIN	Higher potency single analgesic agents	PURDUE PHARMA L	18
MUSE	Prostaglandins for ED	VIVUS	686

**Table 6: (cont) Recommended to retain or be designated non-formulary on Uniform Formulary**

☐ MYAMBUTOL	☐ Antitubercular medications	X-GEN PHARMACEU	1
☐ NEOBENZ MICRO	☐ Keratolytics	SKINMEDICA	223
☐ NIFEREX GOLD	☐ Iron replacement	THER-RX	44
☐ NIFEREX-150 FORTE	☐ Iron replacement	THER-RX	378
☐ NIRAVAM	☐ Anxiolytics	AZUR PHARMA, IN	181
☐ NOVASTART	☐ Prenatal vitamins	AZUR PHARMA, IN	2
☐ NUZON	☐ Topical corticosteroids	WRASER PHARMA	25
☐ OBSTETRIX EC	☐ Prenatal vitamins	SEYER INC.	81
☐ OMNICEF	☐ 3rd gen cephalosporins	ABBOTT LABS.	7
☐ OXANDRIN	☐ Androgens/anabolic steroids	SAVIENT PHARMAC	2
☐ OXISTAT	☐ Topical antifungals	Pharmaderm	2,460
☐ OXSORALEN	☐ Hyperpigmentation agents	VALEANT	9
☐ PAMINE	☐ Anticholinergics/antispasmodics	KENWOOD LAB.	4
☐ PAMINE FORTE	☐ Anticholinergics/antispasmodics	KENWOOD LAB.	1
☐ PAMINE FQ	☐ Anticholinergics/antispasmodics	KENWOOD LAB.	2
☐ PCE	☐ Macrolide	ABBOTT LABS.	16
☐ PEDIAPRED	☐ Oral corticosteroids	UCB PHARMA	4
☐ PENTASA	☐ Medications for inflammatory bowel disease	SHIRE US INC.	1,553
☐ PERCODAN	☐ Higher potency narcotic analgesic combos	ENDO PHARM INC.	34
☐ PERPHENAZINE	☐ Typical antipsychotics	SANDOZ	356
☐ PERSANTINE	☐ Platelet aggregation inhibitors	BOEHRINGER ING.	4
☐ PHOSLO	☐ Phosphate binders	FRESENIUS MED	24
☐ PLETAL	☐ Platelet aggregation inhibitors	OTSUKA AMERICA	9
☐ POLY HIST DM	☐ antitussive-1st gen AH-decongestant	POLY PHARM.	98
☐ POLY HIST FORTE	☐ 1st gen AH-decongestant	POLY PHARM.	514
☐ POLY HIST PD	☐ 1st gen AH-decongestant	POLY PHARM.	19
☐ POLY TAN D	☐ 1st gen AH-decongestant	POLY PHARM.	63
☐ POLY TAN DM	☐ antitussive-1st gen AH-decongestant	POLY PHARM.	154
☐ POLY-TUSSIN DHC	☐ antitussive-1st gen AH-decongestant	POLY PHARM.	939
☐ POLY-TUSSIN DM	☐ antitussive-1st gen AH-decongestant	POLY PHARM.	132
☐ POTASSIUM CHLORIDE	☐ Potassium replacement	SCHERING CORP G	8,159
☐ PRECARE	☐ Prenatal vitamins	THER-RX	245
☐ PRECARE CONCEIVE	☐ Prenatal vitamins	THER-RX	51
☐ PRECARE PREMIER	☐ Prenatal vitamins	THER-RX	473
☐ PREFERA-OB	☐ Prenatal vitamins	ALAVEN PHARMACE	279
☐ PREMESIS RX	☐ Prenatal vitamins	THER-RX	68
☐ PROAMATINE	☐ Adrenergic vasopressors	SHIRE US INC.	4
☐ PROCRI	☐ RBC Stimulants	ORTHO BIOTECH	2,201
☐ P-TEX	☐ 1st gen antihistamines	POLY PHARM.	
☐ QUIXIN	☐ Ophthalmic antibiotics, quinolones	VISTAKON PHARMA	350
☐ RESPA A.R.	☐ 1st gen AH-decongestant-anticholinergic	RESPA PHARM.	503
☐ RESPA-BR	☐ 1st gen antihistamines	RESPA PHARM.	85
☐ RHEUMATREX	☐ Antirheumatics	DAVA PHARMACEUT	10
☐ RIOMET	☐ Biguanides	RANBAXY BRAND D	105
☐ SAIZEN	☐ Growth hormone	EMD SERONO, INC	31
☐ SALAGEN	☐ Parasympathetic agents	EISAI INC.	10
☐ SEDAPAP	☐ Analgesic combos	MERZ	
☐ SEPTRA	☐ Sulfonamides/folate antagonists	MONARCH PHRM	



**Table 6: (cont) Recommended to retain or be designated non-formulary on Uniform Formulary**

ProdName	Subclass	Manufacturer	Sum of Patients
☐ SEPTRA DS	☐ Sulfonamides/folate antagonists	MONARCH PHRM	3
☐ SEROSTIM	☐ Growth hormone	EMD SERONO, INC	3
☐ SILVADENE	☐ Topical sulfonamides	MONARCH PHRM	7
☐ SONATA	☐ Newer sedative hypnotics	KING PHARM	282
☐ SORIATANE CK	☐ Psoriasis medications, oral	STIEFEL LABS.	577
☐ SULFAMYLON	☐ Topical sulfonamides	UDL	13
☐ TAPAZOLE	☐ Antithyroid medications	KING PHARM	6
☐ TEMOVATE	☐ Topical corticosteroids	Pharmaderm	4
☐ TEMOVATE EMOLLIENT	☐ Topical corticosteroids	Pharmaderm	2
☐ TENEX	☐ Sympatholytics	PROMIUS PHARMA	19
☐ TESTRED	☐ Androgens/anabolic steroids	VALEANT	72
☐ THALITONE	☐ Thiazides	MONARCH PHRM	29
☐ TIGAN	☐ Other antiemetics	MONARCH PHRM	2
☐ TINDAMAX	☐ Antiprotozoal	MISSION PHARM.	691
☐ TRANSDERM-SCOP	☐ Other antiemetics	BAXTER HEALTHCA	974
		NOVARTIS CONSUM	6,163
☐ TRETIN-X	☐ Acne meds	TRIAx PHARMACEU	94
☐ ULTRAVATE	☐ Topical corticosteroids	RANBAXY BRAND D	8
☐ ULTRAVATE PAC	☐ Topical corticosteroids	RANBAXY BRAND D	144
☐ VALIUM	☐ Anxiolytics	ROCHE LABS.	249
☐ VESANOID	☐ Misc antineoplastics	ROCHE LABS.	7
☐ VIRAMUNE	☐ HIV antivirals, NNRTIs	BOEHRINGER ING.	52
☐ VIROPTIC	☐ Ophthalmic antivirals	MONARCH PHRM	5
☐ VYVANSE	☐ ADHD medications	SHIRE US INC.	14,885
☐ WELCHOL	☐ Bile acid sequestrants	DAIICHI SANKYO,	7,541
☐ WESTCORT	☐ Topical corticosteroids	RANBAXY BRAND D	
☐ ZAROXOLYN	☐ Thiazides	UCB PHARMA	9
☐ ZONEGRAN	☐ Anticonvulsants	EISAI INC.	85
☐ ZORBTIVE	☐ Growth hormone	EMD SERONO, INC	

**Table 7: Uniform Formulary Implementation Plan Summary – 2007 to present**

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 07	Phosphodiesterase Type 5 Inhibitors (PDE-5 inhibitors) for Erectile Dysfunction	<ul style="list-style-type: none"> <li>▪ sildenafil (Viagra)</li> <li>▪ tadalafil (Cialis)</li> </ul>	14,524 (new users that will hit step)	0	12,086	2438	60 days	Institute step therapy	Yes
		<ul style="list-style-type: none"> <li>▪ sildenafil (Viagra)</li> <li>▪ tadalafil (Cialis)</li> </ul>	See previous meeting below						
Aug 09	Targeted Immunomodulatory Biologics (TIBs)	<ul style="list-style-type: none"> <li>▪ certolizumab (Cimzia)</li> <li>▪ golimumab (Simponi)</li> </ul>	201	25	149	37	60 days	New drug in already reviewed class; low utilization	No
Nov 07		<ul style="list-style-type: none"> <li>▪ etanercept (Enbrel)</li> <li>▪ anakinra (Kineret)</li> </ul>	See previous meeting below						
Aug 07	Alpha-1 blocker BPH Agents	<ul style="list-style-type: none"> <li>▪ silodosin (Rapiflo)</li> </ul>	695	2	559	134	60 days	New drug in already reviewed class; low utilization	Yes
Nov 07		<ul style="list-style-type: none"> <li>▪ tamsulosin (Flomax)</li> </ul>	See previous meeting below						

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 09	Antilipidemic II Agents (LIP-2s)	<ul style="list-style-type: none"> <li>Fenofibrate acid (Trilipix)</li> </ul>	4,037	4	3,128	885	60 days	New drug in already reviewed class; low utilization	
May 07		<i>Update May 07; 1<sup>st</sup> review May 07</i> <ul style="list-style-type: none"> <li>fenofibrate nanocrystallized (Tricor)</li> <li>fenofibrate micronized (Antara)</li> <li>omega-3 fatty acids (Omacor)</li> <li>colesevelam (Welchol)</li> </ul>	See previous meeting below						No
May 09	Overactive Bladder Drugs	<ul style="list-style-type: none"> <li>Fesoterodine ER (Toviaz)</li> </ul>	102	1	86	15	60 days	New drug in already reviewed class; low utilization	No
Aug 08		<i>Update Aug 08; 1<sup>st</sup> review Feb 06</i> <ul style="list-style-type: none"> <li>Tolterodine IR (Detrol)</li> <li>Trospium IR (Sanctura)</li> </ul>	See previous meeting below						No
May 09	Nasal Allergy Drugs	<ul style="list-style-type: none"> <li>Azelastine with Sucralose (Astepro)</li> </ul>	5,269	4	5,037	428	60 days	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Nov 08</i> <ul style="list-style-type: none"> <li>Beclomethasone (Beconase AQ)</li> <li>Budesonide (Rhinocort AQ)</li> <li>Ciclesonide (Omnaris)</li> <li>Fluticasone Furoate (Veramyst)</li> <li>Triamcinolone (Nasacort AQ)</li> <li>Olopatadine (Patanase)</li> </ul>	34,271	440	27,017	6,814	60 (8 Apr 09)	Nasal corticosteroids reviewed Nov 05, no changes to UF other than Patanase and Omnaris made non-formulary (1,794 users)	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 09	PPIs	<ul style="list-style-type: none"> <li>Dexlansoprazole delayed release tabs (Kapidex)</li> </ul>	1,015	0	872	143	60 days	New drug in already reviewed class; low utilization	Yes
		<i>May 07 Update; Feb 05 1<sup>st</sup> review</i> <ul style="list-style-type: none"> <li>lansoprazole (Prevacid)</li> <li>omeprazole/sodium bicarbonate (Zegerid)</li> <li>pantoprazole (Protonix)</li> <li>rabeprazole (Aciphex)</li> </ul>	See previous meeting below						Yes
May 09	Antiemetics	<ul style="list-style-type: none"> <li>Granisetron transdermal system (Sancuso)</li> </ul>	115	3	109	3	60 days	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)	No
		<i>Original Meeting May 06</i> <ul style="list-style-type: none"> <li>Dolasetron (Anzemet)</li> </ul>	852	14	668	170	27 Sept 06 (60 days)	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)	No
Feb 09	Inhaled Corticosteroids	<ul style="list-style-type: none"> <li>Beclomethasone HFA MDI (Qvar)</li> <li>Budesonide DPI (Pulmicort Flexhaler)</li> <li>Ciclesonide HFA MDI (Alvesco)</li> <li>Flunisolide CFC MDI (Aerobid)</li> <li>Flunisolide CFC MDI with Menthol (Aerobid M)</li> <li>Triamcinolone CFC MDI (Azmacort)</li> </ul>	13,489	3,556	7,831	2,102	120 (1 Sep 09)	Lag time to allow implementation of drug classes from Aug 08 and Nov 08	No
Feb 09	Long-Acting Beta Agonists	<ul style="list-style-type: none"> <li>Formoterol inhalation solution (Perforomist)</li> </ul>	109	2	44	63	120 (1 Sep 09)	Lag time to allow implementation of drug classes from Aug 08 and Nov 08	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Feb 09	Inhaled Corticosteroids / Long-Acting Beta Agonist Combinations	<ul style="list-style-type: none"> <li>(no drugs made non-formulary)</li> </ul>	N/A	N/A	N/A	N/A	N/A	N/A	
Nov 08	Inhaled Short Acting Beta Agonist	<ul style="list-style-type: none"> <li>Metaproterenol inhaled solution</li> <li>Pirbuterol CFC MDI (Maxair)</li> </ul>	1,278	44	1,002	232	60 (8 Apr 09)	Small number of beneficiaries affected	No
Nov 08	Nasal Allergy Drugs	<ul style="list-style-type: none"> <li>Beclomethasone (Beconase AQ)</li> <li>Budesonide (Rhinocort AQ)</li> <li>Ciclesonide (Omnaris)</li> <li>Fluticasone Furoate (Veramyst)</li> <li>Triamcinolone (Nasacort AQ)</li> <li>Olopatadine (Patanase)</li> </ul>	34,271	440	27,017	6,814	60 (8 Apr 09)	Nasal corticosteroids reviewed Nov 05, no changes to UF other than Patanase and Omnisar made non-formulary (1,794 users)	No
Aug 08	Self-Monitoring Blood Glucose System Test Strips	<ul style="list-style-type: none"> <li>One Touch (for One Touch Ultra 2, Ultra Mini, and Ultra Smart meters)</li> <li>TrueTrack strips (for TrueTrack meter)</li> <li>Accu-chek Comfort Curve strips (for Accu-chek Advantage meter)</li> <li>Accu-chek Compact Plus drum (for Accu-check Compact Plus meter)</li> <li>Accu-chek Simplicity, Ascensia Autodisk, Ascensia Breeze 2, Ascensia Elite, Assure, Assure 3, Assure II, Assure Pro, Bd Test Strips, Chemstrip Bg, Control AST, Dextrostix Reagent, Easygluco, Easypro, Fast Take, Freestyle test strips (other than Freestyle Lite), Glucofilm, Glucolab, Glucometer Dex, Glucometer Elite, Glucose Test Strip, Glucostix, Optium,</li> </ul>	58,142	12,271	33,658	12,231	120	Allow time for patients to receive new meters	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		Precision Pcx, Precision Pcx Plus, Precision Q-I-D, Precision Sof-Tact, Prestige Smart System, Prodigy, Quicktek, Sidekick, Sof-Tact, Surestep, Surestep Pro, Test Strip, Relion Ultima, Uni-Check ▪ Plus all other store/private label brand strips not included on Uniform Formulary (see the BCF/ECF column)							
Aug 08	Overactive Bladder Drugs	▪ Tolterodine IR (Detrol) ▪ Trospium IR (Sanctura)	4,215	235	1,210	2,770	90	Typical 90-day implementation period	No
Aug 08	Antidepressant – 1s	▪ Desvenlafaxine (Pristiq)	745	0	694	51	60	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Nov 05</i> ▪ paroxetine HCl CR (Paxil) ▪ fluoxetine 90 mg for weekly administration (Prozac Weekly) ▪ fluoxetine in special packaging for PMDD (Sarafem) ▪ escitalopram (Lexapro) ▪ duloxetine (Cymbalta) ▪ bupropion extended release (Wellbutrin XL)	See previous meetings below in table			See previous meetings below in table	See previous meetings below in table	No	
Aug 08	Calcium Channel Blockers	▪ Nisoldipine geomatrix (Sular geomatrix)	2,027	56	1,188	783	60	New drug in already reviewed class; low utilization	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		<i>Original Meeting Aug 05</i> <ul style="list-style-type: none"> <li>▪ amlodipine (Norvasc) <ul style="list-style-type: none"> <li>○ Nov 07: removed from NF status</li> </ul> </li> <li>▪ isradipine IR (Dynacirc)</li> <li>▪ isradipine ER (Dynacirc CR)</li> <li>▪ nicardipine IR (Cardene, generics)</li> <li>▪ nicardipine SR (Cardene SR)</li> <li>▪ verapamil ER (Verelan)</li> <li>▪ verapamil ER for bedtime dosing (Verelan PM, Covera HS)</li> <li>▪ diltiazem ER for bedtime dosing (Cardizem LA)</li> </ul>	See previous meetings below in table				See previous meetings below in table	See previous meetings below in table	No
Jun 08	Triptans	<ul style="list-style-type: none"> <li>▪ Almotriptan (Axert)</li> <li>▪ Frovatriptan (Frova)</li> <li>▪ Naratriptan (Amerge)</li> </ul>	3,763	208	3,212	343	(26 Nov 2008) 90 days	Typical 90-day implementation period	No
Jun 08	Osteoporosis Agents	<ul style="list-style-type: none"> <li>▪ Salmon-calcitonin (Miacalcin)</li> </ul>	2,914	945	1,948	1,021	(26 Nov 2008) 90 days	Typical 90-day implementation period	No
Jun 08	Newer Antihistamines (NAs) (new drug in previously reviewed class); Original decision Aug 07	<ul style="list-style-type: none"> <li>▪ Levocetirizine (Xyzal)</li> </ul>	19,254	0	19,254	0	(29 Oct 2008) 60 days	New drug in already reviewed class	No
		<i>Original Meeting Aug 07</i> <ul style="list-style-type: none"> <li>▪ desloratadine (Clarinet)</li> <li>▪ desloratadine/pseudoephed. (Clarinet D)</li> </ul>	27,396	60	20,102	7,234	See previous meetings below in table	Typical 90-day implementation period	No
Jun 08	Leukotriene Modifiers (LMs) (new drug in previously reviewed class);	<ul style="list-style-type: none"> <li>▪ Zileuton extended release (Zyflo CR)</li> </ul>	288	0	288	0	(29 Oct 2008) 60 days	New drug in already reviewed class; low utilization	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
	Original decision Aug 07	<i>Original Meeting Aug 07</i> <ul style="list-style-type: none"> <li>zileuton (Zyflo)</li> </ul>	144	4	110	31	See previous meetings below in table	Typical 90-day implementation period	No
Jun 08	Beta Adrenergic Receptor Blockers (ABAs) (new drug in previously reviewed class); Original decision Nov 07	<ul style="list-style-type: none"> <li>Nebivolol (Bystolic)</li> </ul>	2,462	0	2,462	0	(29 Oct 2008) 60 days	New drug in already reviewed class; low utilization	No
		<i>Original Meeting Nov 07</i> (No drugs designated non formulary)	0	0	0	0	See previous meetings below in table	No meds moved to non-formulary status	No
Jun 08	Renin Antihypertensive Agents (RAAs) (new drug in previously reviewed class);	<i>ARB/CCB combos (Jun 08)</i> <ul style="list-style-type: none"> <li>Olmesartan / amlodipine (Azor)</li> </ul>	2,641	0	2,641	0	(29 Oct 2008) 60 days	New drug in already reviewed class with current low utilization	No
		<i>ARB/CCB combos (Nov 07)</i> <ul style="list-style-type: none"> <li>valsartan / amlodipine (Exforge)</li> </ul>	2,376	0	2,376	0	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
		<i>ARBs – (May 07 meeting)</i> <ul style="list-style-type: none"> <li>eprosartan (Teveten)</li> <li>eprosartan HCTZ (Teveten HCT)</li> <li>irbesartan (Avapro)</li> <li>irbesartan HCTZ (Avalide)</li> <li>olmesartan (Benicar)</li> <li>olmesartan HCTZ (Benicar HCT)</li> <li>valsartan (Diovan)</li> <li>valsartan HCTZ (Diovan HCT)</li> </ul> <i>ACE/CCB combos – Feb 06 meeting</i> <ul style="list-style-type: none"> <li>felodipine/enalapril (Lexxel)</li> <li>verapamil/trandolapril (Tarka)</li> </ul> <i>ACE Inhibitors (Aug 05 meeting)</i> <ul style="list-style-type: none"> <li>moexipril (Univasc),</li> <li>moexipril / HCTZ (Uniretic)</li> <li>perindopril (Aceon)</li> <li>quinapril (Accupril)</li> <li>quinapril / HCTZ (Accuretic)</li> </ul>	See previous meetings for affected beneficiaries for each subclass				See previous meetings below in table	See previous meetings below in table	



Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		<ul style="list-style-type: none"> <li>ramipril (Altace)</li> </ul>							
Nov 07	Benign Prostatic Hypertension (BPH) Alpha Blockers (ABs)	<ul style="list-style-type: none"> <li>tamsulosin (Flomax)</li> </ul>	64,783	1,426	40,161	23,196	(16 Apr 2008) 60-days	3 <sup>rd</sup> class for Step Therapy	Yes
Nov 07	Targeted Immunomodulatory Biologics (TIBs)	<ul style="list-style-type: none"> <li>etanercept (Enbrel)</li> <li>anakinra (Kineret)</li> </ul>	7,397	1,939	4,149	1,309	(18 Jun 2008) 90-days	Typical 90-day implementation period	No
Nov 07	Attention Deficit Hyperactivity Disorder (ADHD) / Narcolepsy agents (new drug in previously reviewed class); Previous decision Nov 06	<ul style="list-style-type: none"> <li>lisdexamfetamine (Vyvanse)</li> </ul>	2,200 Rxs	0	2,200 Rxs	0	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No
		<i>Original decision Nov 06</i> <ul style="list-style-type: none"> <li>Dexmethylphenidate IR (Focalin)</li> <li>Dexmethylphenidate SODAS (Focalin XR)</li> <li>Methylphenidate transdermal patch (Daytrana)</li> </ul>	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	
Nov 07	Contraceptive Agents (new drug in previously reviewed class); Previous decisions May 06, Nov 06	<ul style="list-style-type: none"> <li>EE 20 mcg / levonorgestrel 0.09 mg (Lybrel)</li> </ul>	290 Rxs	2 Rxs	263 Rxs	25 Rxs	(16 Apr 2008) 60 days	New drug in already reviewed class with current low utilization	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		<p><i>Previous meetings May 06 &amp; Nov 06</i></p> <ul style="list-style-type: none"> <li>▪ EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)</li> <li>▪ EE 25 mcg / norethindrone 0.4 mg (Ovcon 35)</li> <li>▪ EE 50 mcg / norethindrone 1 mg (Ovcon 50)</li> <li>▪ EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe)</li> <li>▪ EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe)</li> <li>▪ EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique)</li> </ul>	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Seasonale, packaged as a 3-month supply; Loestrin 24 FE and Seasonique to coincide with Seasonale decision	
			Seasonique: 161 (from Apr 06-Oct 06)	0 Rxs	112 Rxs	4 Rxs			
			Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs			
Aug 07	Nasal Corticosteroid Agents (new drug in previously reviewed class); Original decision Nov 05	<ul style="list-style-type: none"> <li>▪ fluticasone furoate (Veramyst)</li> </ul>	650	0	650	0	TMOP & TRRx: 60-days for current users; \$22 co-pay in effect immediately for new users MTF: No later than 60 days	New drug in already reviewed class with current low utilization	No
		<p><i>Original Decision: Nov 05</i></p> <ul style="list-style-type: none"> <li>▪ beclomethasone dipropionate (Beconase AQ, Vancenase AQ)</li> <li>▪ budesonide (Rhinocort Aqua)</li> <li>▪ triamcinolone (Nasacort AQ)</li> </ul>					19 Jan 06 (90 days)	Substantial number of beneficiaries	
Aug 07	Growth Stimulating Agents (GSAs)	<ul style="list-style-type: none"> <li>▪ somatropin (Genotropin, Genotropin Miniquick)</li> <li>▪ somatropin (Humatrope)</li> <li>▪ somatropin (Omnitrope)</li> <li>▪ somatropin (Saizen)</li> </ul>	653	77	310	266	TMOP & TRRx: 60-days for current users; MTF: No later than 60 days	Low number of affected beneficiaries affected	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 07	Antilipidemic II Agents (LIP-2s)	<ul style="list-style-type: none"> <li>▪ fenofibrate nanocrystallized (Tricor)</li> <li>▪ fenofibrate micronized (Antara)</li> <li>▪ omega-3 fatty acids (Omacor)</li> <li>▪ colessevelam (Welchol)</li> </ul>	83,612	18,849	44,402	20,361	24 Oct 07 (90 days)	Typical 90-day implementation period	No
May 07	5-Alpha Reductase Inhibitors (5-ARIs)	<ul style="list-style-type: none"> <li>▪ dutasteride (Avodart)</li> </ul>	20,917	1,087	12,830	7,000	24 Oct 07 (90 days)	Typical 90-day implementation period	No
May 07 (Update from Feb 05)	PPIs	<ul style="list-style-type: none"> <li>▪ lansoprazole (Prevacid)</li> <li>▪ omeprazole/sodium bicarbonate (Zegerid)</li> <li>▪ pantoprazole (Protonix)</li> <li>▪ rabeprazole (Aciphex)</li> </ul>	453,525	212,130	178,120	63,275	24 Oct 07 (90 days)	Typical 90-day implementation period	Yes
May 07 (Update from Feb 05)	ARBs	<ul style="list-style-type: none"> <li>▪ eprosartan (Teveten)</li> <li>▪ eprosartan HCTZ (Teveten HCT)</li> <li>▪ irbesartan (Avapro)</li> <li>▪ irbesartan HCTZ (Avalide)</li> <li>▪ olmesartan (Benicar)</li> <li>▪ olmesartan HCTZ (Benicar HCT)</li> <li>▪ valsartan (Diovan)</li> <li>▪ valsartan HCTZ (Diovan HCT)</li> </ul>	228,581	68,059	109,595	50,930	21 Nov 07 (120 days)	Reservations regarding ESI ability to handle implementation	No

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary

CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release

5-ARI = 5-Alpha Reductase Inhibitors; ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GSAs = Growth Stimulating Agents; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; Leukotriene Modifiers = LMs; LIP-1s = Antilipidemic I; LIP-2s = Antilipidemic II; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; NAs = Newer Antihistamines; OABs = Overactive Bladder Medications;

PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; RAAs = Renin Antihypertensive Agents; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

\*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])